Shares of Insulet (PODD) are soaring 5.25% in pre-market trading on Thursday following the company's impressive third-quarter results and raised full-year guidance. The medical device maker, known for its innovative Omnipod insulin delivery system, demonstrated robust growth and beat analyst expectations across key financial metrics.

Insulet reported third-quarter revenue of $706.3 million, surpassing the analyst consensus estimate of $677 million. The company's adjusted earnings per share (EPS) came in at $1.24, exceeding the expected $1.14. This strong performance was primarily driven by increasing demand for its wearable insulin pumps, particularly in international markets.

The company's total Omnipod revenue reached $699.2 million, marking a significant 31% year-over-year increase. Notably, international Omnipod revenue surged by 46.5% (39.9% in constant currency) to $202.1 million, boosted by the integration of Omnipod 5 with Dexcom's G7 continuous glucose monitoring (CGM) sensors in several European countries.

In light of these strong results, Insulet raised its full-year 2025 revenue growth guidance to 28-29%, up from its previous projection of 24-27%. This upward revision reflects the company's confidence in sustained demand for its products and its expanding market presence. The stock's pre-market jump indicates that investors are reacting positively to Insulet's performance and optimistic outlook in the competitive diabetes management market.